2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.
Hayes D, Herbst R, Myles J, Topalian S, Yohe S, Aronson N, Bellizzi A, Basu Roy U, Bradshaw G, Edwards R, El-Gabry E, Elvin J, Gajewski T, McShane L, Oberley M, Philip R, Rimm D, Rosenbaum J, Rubin E, Schlager L, Sherwood S, Stewart M, Taube J, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precision Oncology 2022, 6: e2200454. PMID: 36446042, PMCID: PMC10530621, DOI: 10.1200/po.22.00454.Peer-Reviewed Original ResearchConceptsICI therapyImmune checkpoint inhibition therapyDeath ligand 1 (PD-L1) expressionMultiple predictive biomarkersTumor biomarker testsCheckpoint inhibition therapyLigand 1 expressionDeath ligand 1Field of oncologyICI benefitPredictive factorsPredictive biomarkersInhibition therapyNeoantigen expressionBiomarker testsHealth insurance organizationsUS FoodDrug AdministrationAmerican PathologistsMedicaid ServicesTherapyBiomarker developmentNational InstituteLigand 1Clinical application
2015
Electronic Nicotine Delivery Systems: A Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology
Brandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, Ostroff JS, Shields PG, Toll BA, Tyne CA, Viswanath K, Warren GW. Electronic Nicotine Delivery Systems: A Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology. Journal Of Clinical Oncology 2015, 33: 952-963. PMID: 25572671, DOI: 10.1200/jco.2014.59.4465.Peer-Reviewed Original ResearchConceptsElectronic nicotine delivery systemsClinical OncologyTobacco useAmerican SocietyCancer researchHarm-reduction devicesNumber one preventable causeAmerican AssociationJoint writing groupCombustible tobacco productsClinical cancer researchNicotine delivery systemsCombustible tobacco useAdverse health effectsChildproof capsFormer smokersCigarette smokingPreventable causeTobacco cessationSmoking ratesUS FoodDrug AdministrationENDS useDefinitive dataElectronic cigarettes
2004
Pemetrexed in advanced NSCLC: a review of the clinical data.
Zinner RG, Fossella FV, Herbst RS. Pemetrexed in advanced NSCLC: a review of the clinical data. Oncology 2004, 18: 54-62. PMID: 15339061.Peer-Reviewed Original ResearchConceptsAdvanced NSCLCConcurrent chest radiationPhase II studySecond-line therapyPhase III trialsCell lung cancerFavorable toxicity profileTreatment of mesotheliomaChest radiationII studyIII trialsSystemic dosesThoracic malignanciesFrontline settingLung cancerClinical dataToxicity profilePlatinum agentsSide effectsUS FoodDrug AdministrationPhase IPemetrexedNSCLCNovel mechanism